Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Tristan Herve"'
Autor:
Olivier Mathieu, Genevieve Contant, Matthieu Bourdin, François Depasse, Genmin Lu, Delphine Perrotin, Pamela B. Conley, Tristan Herve
Publikováno v:
International Journal of Laboratory Hematology
Introduction Andexanet alfa (AnXa) was developed for anticoagulant effect reversal of direct factor Xa inhibitors (DXaI) (apixaban, rivaroxaban, edoxaban) in emergency situations. Regular anti‐Xa assays are not suitable to evaluate anti‐Xa activi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b389fa59e5d27121adaa473785fce49
https://pubmed.ncbi.nlm.nih.gov/34092030
https://pubmed.ncbi.nlm.nih.gov/34092030
Autor:
Virginie Cucini, Audrey Carlo, Tristan Herve, Genevieve Contant, Pierre-Olivier Sevenet, François Depasse, Olivier Mathieu
Publikováno v:
International journal of laboratory hematologyREFERENCES. 42(5)
Introduction Directs oral anticoagulants (DOACs) can interfere with coagulation assays, especially in thrombophilia workup. To avoid these interferences, a new device, DOAC Filter, allows the removal of DOACs from citrated plasma. This study aims to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9073c855846fa7563227e157ae5a2dc8
https://pubmed.ncbi.nlm.nih.gov/32567799
https://pubmed.ncbi.nlm.nih.gov/32567799
Autor:
Lisa K. Jennings, Tristan Herve, Genmin Lu, Pamela B. Conley, Jayaprakash Kotha, Matthieu Bourdin, Juan M Cardenas
Publikováno v:
Blood. 136:37-38
Introduction: The anticoagulants rivaroxaban and apixaban inhibit Factor Xa (FXa) activity and are effective therapeutic agents for the prevention and treatment of thromboembolism. Andexanet alfa (andexanet) is the only specific reversal agent approv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c4f4864e807d7cbb4165fc8c748dfbb
https://doi.org/10.1182/blood-2020-140988
https://doi.org/10.1182/blood-2020-140988